Parkinson’s Disease
Parkinson’s disease is a progressive neurological disorder that primarily affects movement. It is named after Dr. James Parkinson, the physician who first described the condition in 1817. Parkinson’s disease develops as a result of the degeneration and loss of dopamine-producing cells in a region of the brain called the substantia nigra.
The exact cause of Parkinson’s disease is still unknown, but it is believed to involve a combination of genetic and environmental factors. There is currently no cure for Parkinson’s disease, but various treatment approaches aim to manage symptoms and improve quality of life. Medications, such as levodopa and dopamine agonists, can help replenish dopamine levels or mimic its effects. Physical therapy, occupational therapy, and speech therapy can assist with mobility, daily activities, and communication. In some cases, deep brain stimulation (DBS) surgery may be recommended to alleviate symptoms.
This magazine contains content which is gathered, validated, categorized, and supplied using a novel big data cyberinfrastructure technology that continually learns about Parkinson’s Disease.
-
Publication date: Jan 15, 2026 Background/Objectives: Parkinson’s disease is the second most common neurodegenerative disorder, ...
-
Neuroimaging and Pathology Biomarkers in Parkinson’s Disease and Parkinsonism.
Publication date: Jan 19, 2026 The “Neuroimaging and Pathology Biomarkers in Parkinson’s Disease” course held ... -
Synergistic Effects of Plant Polysaccharides and Probiotics: A Novel Dietary Approach for Parkinson’s Disease Intervention.
Publication date: Jan 15, 2026 Parkinson’s disease (PD), the second most common neurodegenerative disorder globally, ... -
Parkinson’s Disease: From Gene-Environment Risk to Precision Therapy.
Publication date: Feb 05, 2026 Parkinson’s disease (PD) is a progressive and heterogeneous neurodegenerative disorder ... -
Adaptive deep brain stimulation in Parkinson’s disease.
Publication date: Feb 18, 2026 With the introduction of adaptive deep brain stimulation (aDBS) for ... -
Inhibition of Death-Associated Protein Kinase 1 ameliorates central and peripheral pathological changes in a mouse model of Parkinson’s disease.
Publication date: Feb 19, 2026 Parkinson’s disease (PD) is a multisystem neurodegenerative disorder affecting both ... -
Coupling auditory cues and bilateral transauricular vagus nerve stimulation in parkinson’s disease with freezing of gait: an open-label feasibility study.
Publication date: Mar 04, 2026 Concepts Keywords Feasibility Auditory Freezing Bilateral Parkinson Coupling Transauricular Cues ... -
Aberrant Beta-Band Network Alteration Preceding Freezing of Gait in Parkinson’s Disease.
Publication date: Feb 27, 2026 Freezing of gait (FOG) is a debilitating motor symptom observed ... -
Validating wearable sensors as an assessment tool for Parkinson’s disease.
Publication date: Mar 04, 2026 The International Parkinson and Movement Disorder Society Modified Unified Parkinson’s ... -
Non-invasive brain stimulation for treating cognitive and neuropsychiatric non-motor symptoms in Parkinson’s disease and atypical parkinsonism: a systematic review and meta-analysis of randomized controlled trials.
Publication date: Mar 05, 2026 Open Access PDF Concepts Keywords Motor Atypical parkinsonism Neuropsychiatric Cognition ... -
Coping Behavior in Patients with Parkinson’s Disease Prior to Subthalamic Deep Brain Stimulation and Association with Psychiatric Symptoms, Quality of Life and Neuropsychological Status.
Publication date: Mar 05, 2026 Coping behavior of Parkinson’s disease (PD) patients undergoing subthalamic Deep ... -
Role of LRRK2 in physiological activities, diseases, and therapy.
Publication date: Mar 05, 2026 Leucine-rich repeat kinase 2 (LRRK2) is a critical target for ... -
High intensity interval training for Parkinson’s disease: A scoping review of systemic effects and physiological adaptations.
Publication date: Mar 05, 2026 BackgroundHigh intensity interval training (HIIT) involves vigorous intensity exercise bouts ... -
Dimensional Apathy as a Predictor of Health-Related Quality of Life in Parkinson’s Disease.
Publication date: Mar 05, 2026 Apathy, defined as diminished self-initiated purposeful behavior, is common in ... -
Antidepressant-like effect of hydroxytyrosol in a 1-methyl-4-phenylpyridinium model of Parkinson’s disease in rats.
Publication date: Mar 05, 2026 Concepts Keywords Antidepressant Depression Hydroxytyrosol Forced swim test Neurochem hydroxytyrosol ... -
Commentary: Pesticides and GBA1 pathogenic variants in Parkinson’s disease: An emerging and potentially dangerous association.
Publication date: Mar 05, 2026 We comment here on the recently published paper by Ostentag ... -
Association of peripheral and CSF zinc levels with Parkinson’s disease: A systematic review and meta-analysis.
Publication date: Jun 01, 2026 The possible involvement of numerous chemical elements in the pathogenesis ... -
Advanced Parkinson’s disease treatment patterns in Italy: results from a multicenter observational study.
Publication date: Dec 01, 2026 Substitution therapy with oral levodopa is the primary treatment of ... -
Hair metal dysregulation in Parkinson’s disease: Implications for diagnosis and gut-brain axis involvement.
Publication date: Mar 20, 2026 This study investigated hair metals as potential biomarkers in Parkinson’s ... -
Nutritional Neurology for Parkinson’s: Key to Longevity
Publication date: Mar 05, 2026 An informative seminar exploring how diet can play a powerful ... -
Thriving Through Speech Therapy: Staying Connected: Overcoming Communication Barriers
Publication date: Mar 05, 2026 Communication is at the heart of staying connected – to ...